These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36372295)

  • 1. HIV protease inhibitor attenuated astrocyte autophagy involvement in inflammation via p38 MAPK pathway.
    Chen X; Ding W; Cui X; Wei J; Zhang Y; Zhang X; Zhang T; Zhang Y
    Antiviral Res; 2022 Dec; 208():105463. PubMed ID: 36372295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.
    Taura M; Kariya R; Kudo E; Goto H; Iwawaki T; Amano M; Suico MA; Kai H; Mitsuya H; Okada S
    Free Radic Biol Med; 2013 Dec; 65():778-788. PubMed ID: 23973637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients.
    Karmochkine M; Si Mohamed A; Piketty C; Ginsburg C; Raguin G; Schneider-Fauveau V; Gutmann L; Kazatchkine MD; Belec L
    Antiviral Res; 2000 Sep; 47(3):179-88. PubMed ID: 10974370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.
    Sulkowski MS; Mehta SH; Chaisson RE; Thomas DL; Moore RD
    AIDS; 2004 Nov; 18(17):2277-84. PubMed ID: 15577540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
    Turner D; Schapiro JM; Brenner BG; Wainberg MA
    Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 protease inhibitors. A review for clinicians.
    Deeks SG; Smith M; Holodniy M; Kahn JO
    JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protease Inhibitors, Saquinavir and Darunavir, Inhibit Oligodendrocyte Maturation: Implications for Lysosomal Stress.
    Festa L; Roth LM; K Jensen B; Geiger JD; Jordan-Sciutto KL; Grinspan JB
    J Neuroimmune Pharmacol; 2021 Mar; 16(1):169-180. PubMed ID: 31776836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
    Côté HC; Brumme ZL; Harrigan PR
    J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
    Hoetelmans RM; Meenhorst PL; Mulder JW; Burger DM; Koks CH; Beijnen JH
    Pharm World Sci; 1997 Aug; 19(4):159-75. PubMed ID: 9297727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
    HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.
    Mo H; Lu L; Dekhtyar T; Stewart KD; Sun E; Kempf DJ; Molla A
    Antiviral Res; 2003 Aug; 59(3):173-80. PubMed ID: 12927307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.
    Raugi DN; Smith RA; Ba S; Toure M; Traore F; Sall F; Pan C; Blankenship L; Montano A; Olson J; Dia Badiane NM; Mullins JI; Kiviat NB; Hawes SE; Sow PS; Gottlieb GS;
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2751-60. PubMed ID: 23571535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
    Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
    Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HIV effect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors.
    Gatanaga H; Aizawa S; Kikuchi Y; Tachikawa N; Genka I; Yoshizawa S; Yamamoto Y; Yasuoka A; Oka S
    AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1493-8. PubMed ID: 10580399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors.
    Barreiro P; Camino N; de Mendoza C; Valer L; Núñez M; Martín-Carbonero L; González-Lahoz J; Soriano V
    Int J Antimicrob Agents; 2002 Dec; 20(6):438-43. PubMed ID: 12458138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
    Giandhari J; Basson AE; Sutherland K; Parry CM; Cane PA; Coovadia A; Kuhn L; Hunt G; Morris L
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2248-56. PubMed ID: 26833162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.